Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 10, 2023
August 10, 2023
46edf900-58f2-4f79-bf45-4baa56d25006
Related Documents
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry
Guidance DocumentJanuary 9, 2026Center for Drug Evaluation and Research
Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products
Guidance DocumentNovember 7, 2018Center for Drug Evaluation and Research
Approaches to Assessment of Overall Survival in Oncology Clinical Trials: Draft Guidance for Industry
Guidance DocumentAugust 19, 2025Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox